Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Australian (ASX) Healthcare Sector Analysis

UpdatedJan 25, 2026
DataAggregated Company Financials
Companies125
  • 7D0.4%
  • 3M-11.3%
  • 1Y-26.1%
  • YTD0.6%

Over the last 7 days, the Healthcare industry has remained flat, although notably Pro Medicus declined by 11%. As for the longer term, the industry has declined 26% in the last year. As for the next few years, earnings are expected to grow by 17% per annum.

Sector Valuation and Performance

Has the Australian Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 25 Jan 2026AU$216.3bAU$73.1bAU$4.4b32.7x49.4x3x
Tue, 23 Dec 2025AU$215.8bAU$74.1bAU$4.5b33.4x47.6x2.9x
Thu, 20 Nov 2025AU$217.3bAU$74.8bAU$4.6b31.7x46.9x2.9x
Sat, 18 Oct 2025AU$245.5bAU$75.1bAU$4.6b30.7x52.9x3.3x
Mon, 15 Sep 2025AU$239.7bAU$74.3bAU$4.5b32x52.9x3.2x
Wed, 13 Aug 2025AU$270.0bAU$70.3bAU$4.8b30.2x56x3.8x
Fri, 11 Jul 2025AU$259.5bAU$71.5bAU$4.2b28x61.2x3.6x
Sun, 08 Jun 2025AU$255.5bAU$71.8bAU$4.3b26.1x59.7x3.6x
Tue, 06 May 2025AU$260.4bAU$70.3bAU$4.8b29.3x53.8x3.7x
Thu, 03 Apr 2025AU$251.1bAU$71.1bAU$4.9b28.3x51.2x3.5x
Sat, 01 Mar 2025AU$263.8bAU$71.4bAU$4.9b29.8x53.7x3.7x
Mon, 27 Jan 2025AU$247.0bAU$68.5bAU$3.3b26.3x74.4x3.6x
Wed, 25 Dec 2024AU$244.3bAU$68.8bAU$3.4b25.9x72.9x3.5x
Fri, 22 Nov 2024AU$235.7bAU$67.9bAU$3.2b26x73.8x3.5x
Sun, 20 Oct 2024AU$247.4bAU$67.2bAU$3.1b27.7x80.1x3.7x
Tue, 17 Sep 2024AU$238.6bAU$66.9bAU$3.1b27.4x77.3x3.6x
Thu, 15 Aug 2024AU$239.7bAU$63.8bAU$2.9b29.7x82.7x3.8x
Sat, 13 Jul 2024AU$242.6bAU$62.3bAU$2.6b33.4x94.8x3.9x
Mon, 10 Jun 2024AU$231.4bAU$63.3bAU$2.7b30x86.6x3.7x
Wed, 08 May 2024AU$224.9bAU$61.2bAU$2.6b26.9x85.5x3.7x
Fri, 05 Apr 2024AU$225.2bAU$61.2bAU$2.6b27.6x86.2x3.7x
Sun, 03 Mar 2024AU$223.2bAU$61.7bAU$2.7b26.1x84x3.6x
Tue, 30 Jan 2024AU$228.8bAU$60.4bAU$2.8b25.1x80.5x3.8x
Thu, 28 Dec 2023AU$224.9bAU$59.6bAU$2.7b24.9x82.9x3.8x
Sat, 25 Nov 2023AU$202.1bAU$60.5bAU$2.9b24.9x70.2x3.3x
Mon, 23 Oct 2023AU$187.0bAU$61.4bAU$3.0b24.9x62x3x
Wed, 20 Sep 2023AU$206.0bAU$61.1bAU$2.9b25.3x71.7x3.4x
Fri, 18 Aug 2023AU$211.7bAU$60.5bAU$2.8b27.6x74.6x3.5x
Sun, 16 Jul 2023AU$210.0bAU$57.2bAU$2.8b27.6x74.4x3.7x
Tue, 13 Jun 2023AU$230.0bAU$57.5bAU$2.9b25.5x80.5x4x
Thu, 11 May 2023AU$230.7bAU$57.0bAU$2.8b27.8x81.2x4x
Sat, 08 Apr 2023AU$230.6bAU$57.2bAU$2.9b26.6x80.2x4x
Mon, 06 Mar 2023AU$222.5bAU$56.8bAU$2.8b28.6x78.8x3.9x
Wed, 01 Feb 2023AU$225.7bAU$55.1bAU$3.9b24.9x57.6x4.1x
Price to Earnings Ratio

57.6x


Total Market Cap: AU$225.7bTotal Earnings: AU$3.9bTotal Revenue: AU$55.1bTotal Market Cap vs Earnings and Revenue0%0%0%
Australian Healthcare Sector Price to Earnings3Y Average 69.8x202420252026
Current Industry PE
  • Investors are pessimistic on the Australian Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 49.4x which is lower than its 3-year average PE of 69.8x.
  • The 3-year average PS ratio of 3.6x is higher than the industry's current PS ratio of 3.0x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 3.8% per year over the last three years.
  • Revenues for these companies have grown 9.9% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Australian Healthcare sector?

AU Market-0.29%
Healthcare0.44%
Healthcare Services3.20%
Biotech1.79%
Medical Equipment1.49%
Life Sciences-2.02%
Pharma-2.85%
Healthtech-11.14%
Industry PE
  • Investors are most optimistic about the Healthtech industry which is trading above its 3-year average PE ratio of 2kx.
    • Analysts are expecting annual earnings growth of 26.0%, which is lower than the prior year's growth of 62.7% per year.
Forecasted Growth
  • Analysts are most optimistic on the Life Sciences industry, expecting annual earnings growth of 69% over the next 5 years.
  • This is better than its past earnings growth rate of 2.4% per year.
  • In contrast, the Biotech industry is expected to see its earnings grow by 13% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
CSL CSLAU$179.622.3%
+AU$2.0b		-34.0%PE19.9x
SIG Sigma HealthcareAU$3.065.5%
+AU$1.8b		n/aPE66.4x
AVR Anteris Technologies GlobalAU$9.7540.9%
+AU$609.4m		7.7%PS289.2x
COH CochlearAU$273.731.9%
+AU$341.4m		-13.2%PE46x
CU6 Clarity PharmaceuticalsAU$3.464.2%
+AU$52.1m		-15.6%PS136x

Latest News

AVR
AU$9.75
Anteris Technologies Global
7D
40.9%
1Y
7.7%
RAC
AU$2.66
Racura Oncology
7D
-11.6%
1Y
112.8%
4DX
AU$4.05
4DMedical
7D
-20.3%
1Y
575.0%
MSB
AU$2.68
Mesoblast
7D
1.5%
1Y
-6.6%
TLX
AU$10.95
Telix Pharmaceuticals
7D
-4.6%
1Y
-60.2%
PME
AU$180.92
Pro Medicus
7D
-10.8%
1Y
-33.5%
PNV
AU$1.09
PolyNovo
7D
-9.5%
1Y
-51.6%
SIG
AU$3.06
Sigma Healthcare
7D
5.5%
1Y
n/a

With Sigma Healthcare Limited (ASX:SIG) It Looks Like You'll Get What You Pay For

Jan 17
With Sigma Healthcare Limited (ASX:SIG) It Looks Like You'll Get What You Pay For
SHL
AU$23.34
Sonic Healthcare
7D
0.4%
1Y
-16.6%

SHL: Higher Revenue Assumptions Will Support Attractive Future Earnings Multiple

Analysts have slightly reduced their price targets for Sonic Healthcare, reflecting updated fair value estimates of around $27.68, modestly higher revenue growth assumptions near 7.41% and minor adjustments to profit margin and P/E expectations. Valuation Changes Fair Value Estimate eased slightly from A$28.11 to A$27.68.
EBR
AU$0.94
EBR Systems
7D
-10.9%
1Y
-42.5%
COH
AU$273.73
Cochlear
7D
1.9%
1Y
-13.2%

Investors Shouldn't Overlook Cochlear's (ASX:COH) Impressive Returns On Capital

Jan 11
Investors Shouldn't Overlook Cochlear's (ASX:COH) Impressive Returns On Capital
CSL
AU$179.62
CSL
7D
2.3%
1Y
-34.0%

CSL: Shares Will Recover As Seqirus Reset And Demerger Deferral Settle

Analysts have trimmed their CSL price target slightly, with fair value moving from about A$236.57 to A$232.45, as they factor in softer Seqirus vaccination trends and the deferred vaccine demerger, while still seeing the recent share pullback as an opportunity to re-engage with the stock. Analyst Commentary Recent research on CSL focuses heavily on the updated outlook for Seqirus, the indefinitely deferred vaccine demerger, and where the current share price sits relative to revised fair value estimates.
LDX
AU$0.23
Lumos Diagnostics Holdings
7D
-19.3%
1Y
447.6%

Market Participants Recognise Lumos Diagnostics Holdings Limited's (ASX:LDX) Revenues Pushing Shares 37% Higher

Dec 07
Market Participants Recognise Lumos Diagnostics Holdings Limited's (ASX:LDX) Revenues Pushing Shares 37% Higher
IMR
AU$2.00
Imricor Medical Systems
7D
6.4%
1Y
32.5%

Is Imricor Medical Systems (ASX:IMR) Using Debt In A Risky Way?

Nov 26
Is Imricor Medical Systems (ASX:IMR) Using Debt In A Risky Way?
NEU
AU$17.65
Neuren Pharmaceuticals
7D
-7.8%
1Y
19.8%
CU6
AU$3.46
Clarity Pharmaceuticals
7D
4.2%
1Y
-15.6%